Cargando…
Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral
SUMMARY: A 72-year-old man with no history of diabetes was referred to our department due to hyperglycemia during pembrolizumab treatment for non-small-cell lung carcinoma. His blood glucose level was 209 mg/dL, but he was not in a state of ketosis or ketoacidosis. Serum C-peptide levels persisted a...
Autores principales: | Kusuki, Kazuhisa, Suzuki, Saya, Mizuno, Yuzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219158/ https://www.ncbi.nlm.nih.gov/pubmed/32478673 http://dx.doi.org/10.1530/EDM-19-0152 |
Ejemplares similares
-
Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis
por: Tzoulis, Ploutarchos, et al.
Publicado: (2018) -
New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer
por: Cunha, Clara, et al.
Publicado: (2022) -
A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma
por: Hakami, Osamah A, et al.
Publicado: (2019) -
Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018) -
Spurious HbA1c results in patients with diabetes treated with dapsone
por: Aljenaee, Khaled, et al.
Publicado: (2019)